The disease burden of diabetes mellitus (DM) and its associated cardiovascular complications represent a growing and major global health problem. Recent studies suggest that circulating exogenous endothelial progenitor cells (EPCs) play an important role in endothelial repair and neovascularization at sites of injury or ischemia. Both experimental and clinical studies have demonstrated that hyperglycemia related to DM can induce alterations to EPCs. The reduction and dysfunction of EPCs related to DM correlate with the occurrence and severity of microvascular and macrovascular complications, suggesting a close mechanistic link between EPC dysfunction and impaired vascular function/repair in DM. These alterations to EPCs, likely mediated by multiple pathophysiological mechanisms, including inflammation, oxidative stress, and alterations in Akt and the nitric oxide pathway, affect EPCs at multiple stages: differentiation and mobilization in the bone marrow, trafficking and survival in the circulation, and homing and neovascularization. Several different therapeutic approaches have consequently been proposed to reverse the reduction and dysfunction of EPCs in DM and may represent a novel therapeutic approach to prevent and treat DM-related cardiovascular complications. (Arterioscler Thromb Vasc Biol. 2014;34:1136-1143.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
D iabetes mellitus (DM) is a complex metabolic disorder characterized by impaired glucose metabolism with hyperglycemia. Patients with DM have a 2-to 4-fold increased risk of developing cardiovascular complications compared with nondiabetic controls. 1 This has been attributed to the occurrence of endothelial dysfunction that leads to the initiation and progression of atherosclerotic vascular disease 2 and impaired neovascularization after ischemia induced by hyperglycemia. 3, 4 In patients with impaired glucose metabolism and DM, the vascular endothelium is challenged by inflammation, reactive oxygen species, and deletion of endothelial nitric oxide synthase (eNOS) with resultant endothelial dysfunction. 2, [5] [6] [7] The depletion and dysfunction of the circulating endothelial progenitor cells (EPCs) are thought to underlie the endothelial dysfunction in DM. In this review, the possible mechanisms, functional consequences, and the potential therapeutic approach for impaired EPCs in DM are discussed. A systematic literature search for full-text papers in the English language was performed using MEDLINE, Embase, and the Cochrane library through to February 2014. In the search phrases used, the following terms were combined with the phrase AND Diabetes: endothelial progenitor cells, cardiovascular disease, myocardial infarction, and stroke. mononuclear cells using different culture durations and protocols. [10] [11] [12] Both early and late EPCs are derived from circulating mononuclear cells and may have their distinct role in endothelial repair and vasculogenesis. In brief, early EPCs that emerge after 4 to 7 days of culture originate from the hematopoietic lineage with a limited proliferative potential although they contribute to in vivo neovascularization via secretion of proangiogenic cytokines. Late EPCs appear after 1 to 3 weeks in culture and express CD34 as well as other endothelial markers, such as KDR and CD146. They have a potent proliferative capacity to form mature endothelial cells in vitro. In contrast to early EPCs, late EPC cultures are more difficult to establish and sometimes impossible in some patients with DM and cardiovascular disease. 13 Many clinical studies have demonstrated that number of circulating EPCs is reduced and their function impaired in terms of decreased proliferation, adhesion, and vasculogenesis in patients with type 1 and type 2 DM ( Table I in the online-only Data  Supplement) . Similar alterations in EPCs are observed in patients with type 1 and type 2 DM, suggesting a close mechanistic link between hyperglycemia and the reduction and functional impairment of EPCs. Indeed, the reduction in circulating EPCs seems to correlate with glycemic control or severity of impaired glucose tolerance in subjects with or without established DM, respectively. [14] [15] [16] [17] [18] [19] [20] Similarly, the deleterious effects of hyperglycemia on the number and function of late EPCs have also been reported. Late EPCs were found in an activated state in patients with DM. 21 In vitro hyperglycemia or a diabetic intrauterine environment diminished late EPC colony formation, self-renewal capacity, and capillary-like tube formation. 22 Moreover, decreased secretion of NO and vascular endothelial growth factor (VEGF), reduced activity of superoxide dismutase, and impaired function, such as migration and tube formation, are observed in activated late EPCs after exposure to a hyperglycemic condition 23 or advanced glycation end products. 24 Reduced number and function of EPCs are also more prevalent in patients with type 1 and type 2 DM with diabetic nephropathy [25] [26] [27] [28] and macrovascular 26, [29] [30] [31] [32] [33] complications and correlate with the degree of atherosclerosis. 34 These observations suggest that the burden of DM-related cardiovascular complications correlates with the number and function of EPCs: alterations in EPCs may contribute to the development and progression of atherosclerosis in patients with DM. This has been attributed to the decreased number of EPCs as well as impairment of their function and recruitment to injured vasculature, causing defective endothelial repair and neovascularization ( Figure 1A ). This has been confirmed by experimental studies ( Table II in the online-only Data Supplement) wherein EPCs from patients with DM 35 as well as an animal model of DM exhibited impaired re-endothelialization of an injured artery 36 and limited ability to enhance neovascularization in ischemic tissue. [37] [38] [39] In contrast, a biphasic pattern in the change of EPCs has also been observed: a decreased number of EPCs seen in nonproliferative retinopathy 40, 41 but an increased number and clonogenic potential in patients with DM with proliferative retinopathy. 40, 42, 43 In patients with type 1 DM and early nonproliferative diabetic retinopathy, only dysregulation of late EPCs with increased clonogenic potential but impairment of homing mechanism is observed. 44 Similarly, functional impairments of EPCs are observed in patients with type 1 40 and type 2 43 DM with proliferative retinopathy despite an increase in their number and clonogenic potential. It is likely that the clonogenic potential and thus the number of late EPCs increased with the progression from nonproliferative to proliferative retinopathy. Furthermore, the proangiogenic activities of increasing number of dysfunctional EPCs may contribute to the pathological retinal neovascularization in late-stage diabetic retinopathy.
In addition to neovascularization, EPCs are involved in thrombus recanalization. 45 It has been demonstrated that the presence of late EPCs has both anticoagulant and antifibrinolytic properties. 46 Indeed, hyperglycemia may reduce plasminogen activator inhibitor-1 secretion and, therefore, diminish the antifibrinolytic property of EPCs. 23, 24 Such an impairment of EPC properties may further explain the occurrence of macrovascular complications in patients with DM.
Mechanisms of Alteration of EPCs in DM
Several major mechanisms have been proposed to explain the reduced number and dysfunction of EPCs associated with impaired glucose metabolism and DM. The underlying mechanisms by which hyperglycemia and insulin resistance can induce inflammation, oxidative stress, and deletion of NO have been extensively summarized in other reviews. 2, [5] [6] [7] 47, 48 Moreover, primary or secondary dyslipidemia in patients with DM can also interact with hyperglycemia and insulin to induce EPC dysfunction. In the following section, the deleterious effects of these mechanisms that affect EPCs at multiple stages of their lifecycle are discussed ( Figure 1B ).
Differentiation and Mobilization
Both human and animal studies have demonstrated that DM is associated with pathological changes in the BM, including microangiopathy with microvascular rarefaction, autonomic neuropathy, alteration of the vascular/osteoblastic progenitor niche, and depletion of hematopoietic tissue and the stem cell pool. [49] [50] [51] [52] [53] Although these abnormalities might not cause a major defect in hematopoiesis, they are associated with reduced differentiation and release of EPCs. Experimental 50, 51 and human studies 54, 55 also demonstrate that DM impairs the mobilization of EPCs in response to tissue ischemia or cytokines, such as granulocyte colony-stimulating factor. Among the several different mechanisms, eNOS dysfunction 56 and altered cytokine gradients, for example, stromal-derived factor 1α (SDF-1α) between the BM and ischemic tissues in DM, 50, 55 may play major roles in the impairment of EPC mobilization. SDF-1α is a cytokine that contributes to EPC mobilization by stimulating chemokine receptor type 4 (CXCR4) on the cell VEGF vascular endothelial growth factor June 2014 membrane of EPCs. 57 In DM, the increased BM SDF-1α level resulting from enhanced CD26/dipeptidyl peptidase 4 (DPP-4) activity and the decreased production of SDF-1α in the ischemic tissue lead to a reduced gradient of this chemoattractant to mobilize EPCs from BM to the circulation. 38, 50, 54 One of the mechanisms of action of granulocyte colony-stimulating factor is via the cleavage of SDF-1α through the release of protease CD26/DDP-4 to reduce the local level of chemoattractant and thus mobilize stem cells from the BM. As a result, the increased BM SDF-1α level in DM reduces the ability of granulocyte colony-stimulating factor to mobilize stem cells, including EPCs, from the BM.
Trafficking and Survival
As discussed above, the migration of EPCs to sites of injury/ ischemia is mediated by the gradient of SDF-1α and other chemoattractants, such as VEGF and erythropoietin. In addition to the altered cytokine gradient, decreased NO, increased reactive oxygen species, and advanced glycation end products in DM impair this migration. 39, 50, 52 These pathological processes induced by DM also increase apoptosis and decrease proliferation of EPCs. Both in vitro and in vivo studies have shown that hyperglycemia and its associated lipotoxicity with elevated oxidized low-density lipoprotein increases the senescence or apoptosis of EPCs mediated through multiple different molecular pathways, including interleukin 8, Akt, protein kinase C, and p38 mitogen-activated protein kinase ( Figure 1B) . 47, 48, 50, 58, 59 
Homing and Neovascularization
It has been postulated that homing circulating EPCs to sites of ischemia can contribute to vascular repair by direct transdifferentiation into vascular endothelial cells and indirectly via the secretion of proangiogenic cytokines. [8] [9] [10] [11] As discussed above, the local release and thus the gradient of cytokines, especially SDF-1α, play a pivotal role in EPC homing. The blockade of either SDF-1α or its receptor CXCR4 prevents the recruitment of EPCs to injured sites. 57 In patients with DM, the high glucose environment reduces the level of VEGF and SDF-1 secretion from endothelial cells via the hypoxia-inducible factor/hypoxia-responsible element pathway and DDP-4 activity. 50 The reduced level of these cytokines may then impair the regulation of growth, migration, and survival of EPCs. Alternatively, exogenous administration of SDF-1α reversed the DM-induced EPC dysfunctional homing ( Figure 2 ) and improved neovascularization and wound healing in animal models. 56 In vitro culture of EPCs from patients with DM 35, 60 or from healthy subjects with a high glucose level 61 as well as EPCs from animal models of DM 36, 49, 62, 63 exhibited impaired proliferation and angiogenesis. Similarly, multiple different molecular mechanisms related to hyperglycemia as discussed above have been proposed to explain the functional impairment and reduced survival of EPCs recruited to the sites of ischemia ( Figure 1B) . 47, 48, 50 More recently, altered expression of microRNA, such as microRNA 126 and microRNA 130a, has been implicated in EPC dysfunction mediated through extracellular signal-regulated kinase, VEGF, and the phosphoinositide 3-kinase/Akt/eNOS signal pathway. 64, 65 Therapeutic Avenues to Restore EPC Alterations in DM As summarized in Figure 2 , several different approaches have been investigated to restore the dysregulation and dysfunction of EPCs mediated by DM.
Antidiabetic Agents
Because impaired glucose metabolism with hyperglycemia is the primary initiating event that induces EPC alteration in DM, and EPC dysfunction is closely related to the degree of hyperglycemia, improved hyperglycemic control should be the initial therapeutic target. Indeed, the severity of hyperglycemia seems to be negatively correlated with EPC number and function in patients with DM. [14] [15] [16] [17] [18] [19] [20] In an animal model of type 1 DM, successful restoration of normoglycemia by islet transplantation increased the number of EPCs and improved their angiogenic function. 66 Currently, there are only limited data on the optimal antidiabetic therapy to reverse EPC dysfunction in DM. Insulin therapy improves the clonogenic potential of EPCs in vitro 67 and increases the number of EPCs in patients with type 2 DM. 68 Metformin improved glycemic control and increased the number of EPCs in patients with type 2 DM. 69 Nonetheless, add-on sulfonylureas (gliclazide) to metformin 70 or thiazolidinediones 71 were more effective than metformin alone in increasing circulating EPCs in patients with type 2 DM despite similar glycemic control. In addition to the hypoglycemic effect, thiazolidinediones have been shown to increase EPC production, reduce EPC apoptosis, and enhance their migratory capacity and reendothelization of injured artery via the activation of the Akt/ eNOS pathway, as well as anti-inflammatory and antioxidative actions. 28, 35, 59, 72 Glucagon-like peptide-1 agonist and DPP-4 inhibitors are a newer class of antidiabetic agents that act by increasing the Figure 2 . Potential therapeutic avenues to restore endothelial progenitor cell (EPC) number and functions for the prevention of macrovascular and microvascular complications in diabetes mellitus (DM). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; DDP-4, dipeptidyl peptidase 4; EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor; miR, microRNA; PVD, peripheral vascular disease; and TZD, thiazolidinedione. June 2014 incretin level to inhibit glucagon release and thus increase insulin secretion. Experimental studies show that the glucagon-like peptide-1 agonist 73 and DPP-4 inhibitor (sitagliptin) 74 improve the function of EPCs in DM. Interestingly, in patients with type 2 DM, DDP-4 inhibitor increased the plasma level of SDF-1α via the suppression of its degradation by CD26/ DDP-4 activity and thus enhanced EPC mobilization from the BM as discussed above. 75 In contrast, there is potential concern in the application of these incretin-based therapies to mobilize EPCs in patients with DM. Recent human studies suggested that DDP-4 inhibitor (sitagliptin) or glucagon-like peptide-1 agonist (exenatide) can induce marked β-cell hyperplasia and increase the prevalence of preneoplastic lesions. 76 The mobilization of BM EPCs by these incretin-based therapies may promote pancreatic tumor angiogenesis and growth in vivo. 77
Approaches to Restore BM Mobilization
Other than DDP-4 inhibitor, increased mobilization of EPCs from the BM in DM can be achieved by the administration of granulocyte colony-stimulating factor or erythropoietin, as well as the blockade of CXCR4 receptor in the BM using AMD3100 (Mozobil). This decreases the binding of SDF-1α to reduce the retention of EPCs. 78 Previous clinical studies suggest that daily thiamine intake is associated with the level of circulating EPCs in patients with type 2 DM; thus, thiamine deficiency may be linked to impaired EPC mobilization. 79 Experimental studies have demonstrated that treatment with benfotiamine, a liposoluble vitamin B 1 with much higher bioavailability compared with thiamine, can reduce oxidative stress and activate the Akt/eNOS pathway to restore EPC number and their mobilization in BM. 11, 49 γ-Tocotrienol, a vitamin E isoform, has also been shown to enhance mobilization of EPCs via increased expression of VEGF. 80 Whether these vitamin supplements can restore the EPC number and function and thus improve vascular function in patients with DM requires future study.
Approaches to Improve EPC Function and Survival
Several other therapeutic approaches or agents that are commonly used in patients with DM to prevent or treat cardiovascular disease can also improve EPC number and function via different mechanisms. In addition to their lipid-lowering effect, statins have many pleiotropic effects that may explain their cardiovascular benefit. Both experimental 81, 82 and clinical studies 83 demonstrate that statins increase the number and function of circulating EPCs by increasing the bioavailability of NO and reducing oxidative stress and apoptosis of EPCs. Blockade of the renin-angiotensin system with angiotensinconverting enzyme inhibitors or angiotensin receptor blockers has also been shown to increase EPC number in patients with DM, 84, 85 possibly mediated by their anti-inflammatory and antioxidative actions through the suppression of angiotensin II. 86 In addition, a combination of statin and angiotensin receptor blocker seems to have a synergistic effect to increase the number and function of EPCs in DM. 85, 87 Lifestyle modifications, including exercise 88 and weight reduction, 89 have also been shown to increase EPC number and function in patients with cardiovascular disease or DM.
Biological Therapies
Several different biological therapies that target the pathophysiological mechanisms of DM-mediated EPC dysfunction have been proposed. Several strategies by priming EPCs have been proposed to improve the function of EPCs in diabetic condition. The use of placenta growth factor has been shown to enhance EPC differentiation and improve postischemic neovascularization in diabetic mice. 90 Pretreatment of EPCs with proangiogenic growth factors, including VEGF, basic fibroblast growth factor, and platelet-derived growth factor, improves incisional wound healing (as assessed by angiogenesis assay, Matrigel assay, and vessel densities) in diabetic mice. 91 Furthermore, in vitro treatment with ephrin-B2/Fc improves the adhesion and migration of peripheral blood mononuclear cells, raises the number of circulating vascular progenitor cells, and enhances their proangiogenic potential in the diabetic mouse model. 92 Moreover, folic acid treatment also shows to normalize the majority of the altered gene expression profiles of EPCs from patients with type 1 DM compared with healthy subjects. 93 In the diabetic mouse model, the overexpression of eNOS in EPCs improves their proangiogenic and antiatherogenic properties. 94 Interestingly, recent studies have suggested that hydrogen sulfide has proangiogenic effects, which improve wound healing via the restoration of EPC functions in diabetic mice. 95 Similarly, direct administration of cytokines or a gene vector encoding those cytokines, such as SDF-1α 56 and VEGF, 96 or a cocktail of these cytokines derived from cultured EPCs of healthy pluripotent cell lines, such as human embryonic stem cells, 97 can reverse EPC dysfunction in patients with DM. Although the number of EPCs in patients with DM did not correlate with the plasma level of adiponectin, 19 treatment of EPCs with adiponectin prevented their senescence induced by hyperglycemia. 50 Because downregulation 64, 65 of microRNA can contribute to EPC dysfunction in DM, microRNA-based treatment to restore the expression of microRNA 126 and microRNA 130a may be a potential novel therapeutic approach.
Finally, a direct delivery of EPCs isolated from BM to the injured/ischemia tissue may reverse the trafficking and homing defects induced by DM. Nevertheless, the proliferative and angiogenic capacity of exogenous EPCs is impaired in DM. An exogenous source of EPCs such as those derived from pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, can avoid this issue. 13 Nonetheless, other issues related to the use of such cell sources, such as risk of immune rejection and tumor formation, need to be addressed.
Future Perspectives
Although an association between endothelial dysfunction and vascular complications in DM is well established, emerging data from experimental and clinical studies suggest that alterations of EPCs may play a pivotal role in the development of microvascular and macrovascular complications. Current therapies that aim to control hyperglycemia, dyslipidemia, and hypertension have been shown to improve EPC number and function in patients with DM. It is unclear whether these improvements are simply a result of the control of these conventional risk factors or independent effects. More importantly, whether the additional pleiotropic effect of these agents on EPCs can further prevent microvascular and macrovascular complications in DM is also unknown. For example, thiazolidinediones seem to provide better improvement in EPCs compared with metformin, yet they fail to demonstrate any benefit on clinical outcomes in patients with DM. 98 It is possible that existing methods used to determine EPCs are misleading. Indeed, EPCs are a heterogeneous population of progenitor cells with different stages of differentiation, and their surface marker profiles change throughout their lifespan. 10 Furthermore, EPCs possess different phenotypes including a proinflammatory (harmful) or angiogenic (protective) capacity, depending on their surrounding environment. 99 Therefore, the balance between the proportions of EPCs with these different phenotypes may play an important role in the pathogenesis of vascular diseases.
For the assessment of EPCs, the enumeration of EPCs based on their phenotypes, that is, early versus late EPCs as well as their in vitro and in vivo functional capacity, should be a preferable surrogate marker compared with simple measurement of EPCs as defined by the expression of surface markers. However, further standardization of cell isolation methods and culture protocols is urgently needed to allow future comparison between different studies. Moreover, future studies are needed to compare the uses of different agents and approaches, alone and in combination, as optimal therapeutic approaches to improve EPC function and thus clinical outcome in patients with DM. 
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Diabetes mellitus and its associated cardiovascular complications represent major health threats. This review summarizes the recent understandings on the pathophysiological role of circulating exogenous endothelial progenitor cells on the occurrence and severity of microvascular and macrovascular complications, as well as the potential novel therapeutic approaches to prevent and treat diabetes mellitus-related cardiovascular complications via the restoration of endothelial progenitor cell number and function in diabetes mellitus.
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